AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...

Trump's return to the White House has introduced significant uncertainty for investors in the medical device industry. Major ...

DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based company specializing in medical diagnostics with its AI-driven DeepView® System, has announced its expected financial outcomes for the year ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...